- Home
- LBRX vs HQL Comparison
LBRX vs HQL Comparison
Compare LBRX & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LBRX | HQL |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 490.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LBRX | HQL |
|---|---|---|
| Price | $25.69 | $16.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $50.67 | N/A |
| AVG Volume (30 Days) | ★ 209.4K | 105.4K |
| Earning Date | 05-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $10.55 |
| 52 Week High | $27.55 | $17.80 |
Technical Indicators
Market Signals| Indicator | LBRX | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 55.96 |
| Support Level | $22.39 | $16.40 |
| Resistance Level | $27.55 | $17.40 |
| Average True Range (ATR) | 1.49 | 0.36 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 63.31 | 88.70 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.